Linked Life Data

18204260

Source:http://linkedlifedata.com/resource/pubmed/id/18204260

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-1-21
pubmed:abstractText
Recent progress in both basic and clinical research has led us to develop sophisticated and effective medical therapy of ulcerative colitis (UC). Although classical agents such as aminosalicylates, corticosteroids and immunomodulatory drugs have remained as the gold standard for decades, their novel formulations and/or dosage regimens have changed their placements in the medical management of UC. In addition, studies have shown that a number of novel therapeutic agents, designed to target specific mechanisms involved in the inflammatory cascade, have efficacy for the treatment of UC and they will have significant clinical impacts in the near future. A clear understanding of the proven and potential benefits of both the standard and emerging therapies will be required for the optimum individual care of patients with varied clinical presentations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1421-9867
pubmed:author
pubmed:copyrightInfo
2008 S. Karger AG, Basel
pubmed:issnType
Electronic
pubmed:volume
77 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
36-41
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.
pubmed:affiliation
Department of Advanced Therapeutics for GI Diseases, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't